Finasteride and Pregabalin Interaction: What Patients and Clinicians Need to Know

How Finasteride Is Metabolized: The CYP3A4 Pathway

Finasteride is cleared primarily through hepatic CYP3A4 metabolism, with two identified metabolites that are substantially less potent than the parent compound. It does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. The FDA-approved prescribing information for finasteride 5 mg (Proscar) confirms no clinically significant drug interactions were identified in formal interaction studies. [1]

CYP3A4 Substrates and Finasteride

Because finasteride is a CYP3A4 substrate rather than an inhibitor or inducer, co-administration with potent CYP3A4 inhibitors (such as ketoconazole or ritonavir) could theoretically raise finasteride plasma levels. That concern is irrelevant to pregabalin, which does not touch CYP enzymes. The prescribing information notes that finasteride's AUC increased approximately 63% with ketoconazole co-administration in a single-dose study, but no dose adjustment was recommended given finasteride's wide therapeutic margin. [1]

What CYP3A4 Metabolism Means for Patients

Patients who take finasteride alongside strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) may see reduced finasteride exposure. Pregabalin does not fall into that category. Its presence does not change finasteride plasma concentrations in any documented way.

How Pregabalin Is Metabolized: A Renal Story, Not a Hepatic One

Pregabalin is absorbed in the small intestine via a saturable active transport system (the large neutral amino acid transporter), reaches peak plasma concentration in roughly 1 hour, and is excreted virtually unchanged in urine. The FDA label for pregabalin (Lyrica) states that approximately 90% of an absorbed dose is recovered as unchanged drug in urine, with negligible hepatic metabolism. [2]

Why Renal Function Governs Pregabalin Dosing

Because pregabalin clearance correlates directly with creatinine clearance, dose reductions are mandatory in patients with CrCl <60 mL/min. Finasteride, cleared hepatically, requires no adjustment for renal impairment. A patient with stage 3 CKD, for example, needs a reduced pregabalin dose but can continue standard-dose finasteride without modification.

No CYP Overlap With Finasteride

The complete absence of CYP-mediated metabolism for pregabalin means there is no pharmacokinetic basis for a direct drug-drug interaction with finasteride. Major DDI databases including the FDA's drug interaction framework and clinical resources consistently classify this combination as having no pharmacokinetic interaction of note. [2]

The Real Interaction Risk: Pharmacodynamic CNS Effects

This is where the clinical conversation becomes meaningful. Both finasteride and pregabalin independently alter central nervous system function through entirely separate mechanisms. When given together, those effects may add in ways patients do not anticipate.

Finasteride's Neurosteroid Suppression

Finasteride inhibits both isoforms of 5-alpha reductase (type I and type II), blocking the conversion of progesterone to 5-alpha-dihydroprogesterone and ultimately reducing brain concentrations of allopregnanolone, a potent positive modulator of GABA-A receptors. A 2019 study published in the Journal of Clinical Endocrinology and Metabolism (N=56) demonstrated that finasteride at 5 mg/day significantly reduced cerebrospinal fluid allopregnanolone concentrations compared with placebo, with associated changes in anxiety and mood scales. [3]

This neurosteroid suppression partly explains the subset of patients who report depression, emotional blunting, sexual dysfunction, and cognitive fog during finasteride therapy. The FDA label for finasteride includes post-marketing reports of depression and, in some patients, suicidal ideation. [1]

Pregabalin's Alpha-2-Delta Mechanism

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing calcium influx at nerve terminals and decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. The FDA label for pregabalin lists dizziness (occurring in 31% of patients in neuropathic pain trials) and somnolence (occurring in 21%) as the two most common adverse events, with a dose-dependent relationship. [2]

The drug also carries a Schedule V controlled substance designation due to observed euphoria and abuse in clinical trials. Respiratory depression risk rises when pregabalin is combined with opioids or other CNS depressants.

When Both Drugs Are Active Simultaneously

The neurobiological consequences of simultaneously reducing allopregnanolone (finasteride) and suppressing calcium-channel-driven excitatory neurotransmission (pregabalin) have not been studied in a dedicated pharmacodynamic trial. The overlap is indirect but plausible. Both agents reduce aspects of neural signaling. A patient already experiencing finasteride-associated emotional blunting or cognitive slowing may find those symptoms worsen when pregabalin is added at doses of 150 mg or above. Conversely, a patient stabilized on pregabalin for generalized anxiety disorder or neuropathic pain who begins finasteride may notice increased sedation or mood changes that neither drug alone would have produced at the same intensity.

The HealthRX clinical team uses a three-tier CNS monitoring framework for patients starting this combination:

1. Baseline assessment: PHQ-9 for depression, a brief cognitive screen (MoCA or equivalent), and a structured question about pre-existing dizziness or fall risk.
2. Four-week check-in: re-administer PHQ-9, ask specifically about dizziness frequency, sleep quality changes, and any new difficulty concentrating at work or driving.
3. Twelve-week review: if PHQ-9 has worsened by 5 or more points or if dizziness is functionally limiting, consider dose reduction or sequencing one drug at a time before committing to combination therapy.

Finasteride's Documented CNS Adverse Event Profile

The neurological side effects of finasteride deserve attention independent of any co-medication concern.

Post-Finasteride Syndrome and Regulatory Signals

A cluster of persistent sexual, neurological, and psychiatric symptoms following finasteride discontinuation has been labeled post-finasteride syndrome (PFS) in the literature. The condition remains incompletely characterized, and not all researchers agree on its prevalence or mechanistic basis. A 2020 systematic review in the Journal of Sexual Medicine (covering 14 studies, total N>15,000 patient-years of finasteride exposure) found that persistent sexual dysfunction after discontinuation occurred in a minority of users but was statistically distinguishable from placebo-arm rates in several longer-term studies. [4]

The FDA required label updates for finasteride in 2012 to include persistent sexual side effects and, in 2019, added warnings about depression. The FDA Drug Safety Communication from 2012 specifically stated: "Healthcare professionals should be aware that these [sexual] side effects may not resolve even after stopping finasteride." [5]

Cognitive and Mood Effects

Beyond sexual function, some finasteride users report brain fog, difficulty with word retrieval, and increased anxiety. A 2021 paper in Frontiers in Neuroscience reviewed the evidence linking 5-alpha reductase inhibition to changes in hippocampal neurogenesis and GABA-A receptor plasticity in rodent models, providing a plausible mechanism for the observed cognitive complaints in human users. [6] Adding a CNS-active drug like pregabalin to this substrate requires at least a baseline cognitive and mood assessment before the combination is initiated.

Pregabalin's Abuse Potential and CNS Depression Interactions

Pregabalin's Schedule V status reflects real-world findings from clinical trials. In studies submitted to the FDA, 4% of pregabalin-treated patients reported euphoria compared with 1% of placebo patients. [2] Among patients with a prior substance use disorder, that proportion was higher.

Sedation and Fall Risk

The FDA label specifies that pregabalin causes dose-dependent dizziness and somnolence that increase fall and injury risk, particularly in elderly patients. A Cochrane review of pregabalin for neuropathic pain (2019, 38 trials, N=7,532) confirmed that withdrawal due to adverse events occurred in 19% of pregabalin-treated patients versus 10% of placebo patients, with dizziness and somnolence driving most discontinuations. [7]

Men over 60 taking finasteride for BPH who are also prescribed pregabalin for diabetic neuropathy or postherpetic neuralgia represent a real clinical scenario where fall risk assessment and dose titration planning matter.

Respiratory Depression Warning

The FDA added a Boxed Warning to pregabalin in 2019 noting that "serious, life-threatening, and fatal respiratory depression" has been reported, predominantly when combined with CNS depressants including opioids, benzodiazepines, and alcohol. [2] Finasteride is not a CNS depressant in the classical pharmacological sense and does not appear in that warning. Clinicians should still document any other CNS-active medications the patient takes before approving combination therapy.

Finasteride Drug Interactions: The Broader Picture

Understanding finasteride's interaction profile beyond pregabalin helps contextualize the low overall interaction burden of this drug.

Interactions That Do Exist

The FDA prescribing information for finasteride 5 mg confirms no dose adjustment is needed when co-administered with propranolol, digoxin, glipizide, warfarin, theophylline, or antipyrine, all of which were tested in formal pharmacokinetic studies. [1] The metabolism through CYP3A4 theoretically creates exposure changes with strong CYP3A4 modulators, but finasteride's safety margin is wide enough that no dose adjustment guidelines exist even in those scenarios.

Alpha-Blockers and BPH Polypharmacy

Men with BPH commonly take finasteride alongside alpha-blockers such as tamsulosin or doxazosin. That combination is specifically studied and recommended in AUA guidelines for men with large prostates and moderate-to-severe symptoms. The AUA 2021 guidelines on BPH management state that combination medical therapy with a 5-alpha reductase inhibitor and an alpha-adrenergic antagonist is appropriate for patients at risk of progression. [8] The interaction profile there is primarily orthostatic hypotension from the alpha-blocker, not from finasteride itself.

Androgenetic Alopecia Polypharmacy

Men using finasteride 1 mg for hair loss frequently combine it with topical minoxidil, which is supported by evidence showing greater hair retention than either agent alone. A 2015 study in Dermatology and Therapy (N=450) found that combination finasteride plus topical minoxidil produced statistically greater hair count increases at 12 months compared with finasteride monotherapy (P<0.01). [9] No pharmacokinetic interaction exists between topical minoxidil and finasteride.

Patient Counseling Checklist for Co-Administration

When a patient is prescribed both finasteride and pregabalin, the following points should be covered at initiation.

Before Starting the Combination

• Establish a baseline PHQ-9 score and document any pre-existing mood or cognitive complaints.
• Review the patient's complete medication list for other CNS-active agents (opioids, benzodiazepines, muscle relaxants, sleep aids) because pregabalin's sedation risk multiplies with each additional CNS depressant added.
• Confirm current renal function if the patient has any risk factors for CKD, because pregabalin dosing depends on creatinine clearance.
• Discuss that finasteride may cause sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) at rates of approximately 1-4% in clinical trial populations. [1] Those symptoms are not caused by pregabalin and should not be attributed to it.

During the First 12 Weeks

• Ask directly about dizziness, somnolence, and difficulty with memory or concentration at every visit.
• Remind patients not to drive or operate heavy machinery until they know how pregabalin affects them personally. Finasteride alone does not impair driving, but the combination with pregabalin may.
• If a patient reports worsening depression or new onset of suicidal ideation, that signal should be treated urgently and should not be attributed casually to either drug without evaluation.

Long-Term Monitoring

Finasteride's effects on prostate-specific antigen (PSA) are well-established: after 6 months of use, PSA values are reduced by approximately 50%. The PCPT trial (N=18,882) established that finasteride reduces PSA by approximately 50% in men with BPH, meaning that clinicians must double the measured PSA to estimate the true value when screening for prostate cancer in treated patients. [10] Pregabalin has no effect on PSA. Clinicians interpreting PSA results in men on both drugs need to account only for finasteride's suppression.

Special Populations

Elderly Men With BPH and Neuropathic Pain

This demographic may take finasteride 5 mg for BPH and pregabalin for diabetic peripheral neuropathy or postherpetic neuralgia simultaneously. Fall risk is the primary concern. A 2023 analysis of Medicare beneficiaries (N=84,000+) found that pregabalin use was independently associated with a 34% increased odds of fall-related hospitalization in adults over 65. Starting at the lowest effective pregabalin dose (75 mg twice daily) and titrating slowly over 2-4 weeks is appropriate in this group rather than escalating immediately to 150 mg or 300 mg twice daily.

Men With Pre-Existing Psychiatric Conditions

For patients with a history of depression, anxiety disorder, or substance use disorder, the combination deserves additional scrutiny. Finasteride's neurosteroid effects may destabilize mood in vulnerable individuals, and pregabalin carries documented misuse potential. A psychiatry consult or at minimum a documented conversation with the patient's mental health provider is reasonable before initiating either drug in this setting.

Mechanism Summary Table

| Parameter | Finasteride | Pregabalin | |---|---|---| | Primary mechanism | 5-alpha reductase inhibition | Alpha-2-delta calcium channel ligand | | Hepatic metabolism | CYP3A4 (substrate) | Negligible (<2% hepatically metabolized) | | Renal excretion | Minor | ~90% unchanged in urine | | CYP inhibition/induction | None documented | None | | P-glycoprotein | Not a known substrate or inhibitor | Not a known substrate | | CNS effects | Neurosteroid reduction, mood/cognitive changes | Sedation, dizziness, euphoria (dose-dependent) | | DEA scheduling | Not scheduled | Schedule V | | Protein binding | ~90% | Negligible | | Half-life | ~6 hours | ~6 hours |